NF-κB inducing kinase (NIK) Novel target for cholangiocarcinoma

Molecular targeted drugs targeting the NIK associated with the differentiation factor from hepatocytes to cholangiocarcinoma

Proposal for Joint Research & Development of Uterine Sarcoma Therapeutics

We are seeking collaborative partners for the non-clinical and clinical development of uterine sarcoma drugs that are inhibitors of cell cycle-related genes CDK1, CDK2, CHEK1, CHEK2, Aurora Kinase B, PLK1, or TTK (Mps1).

Target Discovery and Drug Evaluation using Cancer Stem Cells (CSCs)

We provide CSCs that can be subcultured for a long period of time, which have been enriched and purified from human cancer cells using our proprietary method. We propose joint research projects using these CSCs.

PeriCyto: A Companion Diagnostics for Immune Checkpoint Inhibitors

Prediction of the efficacy of cancer immunotherapy using the tumor-targeting activity of T cells in peripheral blood.

Efficient method for the production of liposomes containing hydrophilic substances

Efficient encapsulation of hydrophilic small molecules and medium molecular weight drugs such as nucleic acids and peptides in liposomes

A whole-animal platform for exploring pancreatic cancer drug and combination therapy thereby

Drosophila models for human PDAC genotype

Therapeutic Targets in Osteosarcoma

Potent Solubilizer for Low-Solubility Aromatic Compounds and its Use

Solubilizer use for experimental formulation of low-solubility seed/hit compounds to evaluate the in vivo drug potency of such compounds.

Liver organoid model containing human hepatocytes for pharmacokinetic assay

Original method and hepatocyte reproduced hepatobiliary function

STING Ligand Loaded Nano DDS for Cancer Immunotherapy

Original lipid nano particles(LNPs) with INF stimulator(Cyclic-di-GMP) showed dramatic activity as a cancer adjuvant.

5-Fluorouracil / Doxorubicin / Gemcitabine based Prodrugs Targeting Hypoxia

Protection of active site by 2-nitroimidazole is released in hypoxia

4th generation EGFR-TKI

Tyrosine kinase inhibitor(TKI) for drug-resistant EGFR mutant